janiecbros/E+ via Getty Images Fate Therapeutics ( NASDAQ: FATE ) disclosed on Friday that chief financial officer Edward Dulac will resign from the company, effective June 14. FATE added that it plans to appoint Scott Wolchko, president and CEO, as the CFO, principal financial and accounting officer, effective immediately after Dulac’s resignation. According to FATE, Wolchko previously served as the CFO of the company from the commencement of its operations until August 2020.
SEC Filing More on Fate Therapeutics Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom Fate Therapeutics: Looking For A Potential Turnaround In 2024 Fate Therapeutics Q1 2024 Earnings Preview Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement.
